Carlos Morel

FIOCRUZ/CDTS, Oswaldo Cruz Foundation, Ministry of Health, Brazil

Carlos M. Morel

Institution:
Oswaldo Cruz Foundation (Fiocruz), Ministry of Health, Rio de Janeiro, Brazil

Academic positions:
Director, Center for Technological Development in Health (CDTS), FIOCRUZ

Previous positions (in the last five years):
1998-2004 Director of The Special Programme for Research and Training in Tropical Diseases (TDR), an independent global programme of scientific collaboration. Established in 1975 and co-sponsored by the United Nations Children's Fund (UNICEF), the United Nations Development Programme (UNDP), the World Bank and the World Health Organization (WHO).

Additional information:
LinkedIn: http://www.linkedin.com/in/carlosmorel
Curriculum Lattes: http://lattes.cnpq.br/9572057540597014

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Public Health & Epidemiology > Global Health (since 16 August 2006)

Links

http://www.fiocruz.br

All recent recommendations

• 9.0
  Identification of Information Flow-Modulating Drug Targets: A Novel Bridging Paradigm for Drug Discovery.
  Recommended by Carlos Morel
  
• 3.0
  Trypanosoma cruzi Parasitemia in US Blood Donors with Serologic Evidence of Infection.
  Recommended by Carlos Morel
  
• 6.0
  SuperPred: drug classification and target prediction.
  Recommended by Carlos Morel
  
• 3.0
  Drug-induced cure drives conversion to a stable and protective CD8(+) T central memory response in chronic Chagas disease.
  Recommended by Carlos Morel
  
• 9.0
  Effect of city-wide sanitation programme on reduction in rate of childhood diarrhoea in northeast Brazil: assessment by two cohort studies.
  Recommended by Carlos Morel
  
• 6.0
  Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening.
  Recommended by Carlos Morel
  
• 3.0
  Epidemiology of Chagas disease in non endemic countries: the role of international migration.
  Recommended by Carlos Morel
  
• 6.0
  A critique of the molecular target-based drug discovery paradigm based on principles of metabolic control: Advantages of pathway-based discovery.
  Recommended by Carlos Morel
  
• 3.0
  A urine-based polymerase chain reaction method for the diagnosis of visceral leishmaniasis in immunocompetent patients.
  Recommended by Carlos Morel
  
• 6.0
  Mother-to-child transmission of Chagas' disease in North America: why don't we do more?
  Recommended by Carlos Morel
  
• 3.0
  Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
  Recommended by Carlos Morel
  
• 9.0
  A synthetic maternal-effect selfish genetic element drives population replacement in Drosophila.
  Recommended by Carlos Morel
  
• 6.0
  Transgenic malaria-resistant mosquitoes have a fitness advantage when feeding on Plasmodium-infected blood.
  Recommended by Carlos Morel
  
• 3.0
  Drug policy for visceral leishmaniasis: a cost-effectiveness analysis.
  Recommended by Carlos Morel
  
• 3.0
  Specific treatment for Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic phase of Chagas disease.
  Recommended by Carlos Morel
  
• 3.0
  Chemically engineered extracts as an alternative source of bioactive natural product-like compounds.
  Recommended by Carlos Morel
  
• 3.0
  Rare essentials: drugs for rare diseases as essential medicines.
  Recommended by Carlos Morel
  
• 6.0
  C-terminal signal sequence promotes virulence factor secretion in Mycobacterium tuberculosis.
  Recommended by Carlos Morel
  
• 3.0
  Evaluation and lead optimization of anti-malarial acridones.
  Recommended by Carlos Morel
  
• 3.0
  Natural products from plants as drug candidates and lead compounds against leishmaniasis and trypanosomiasis.
  Recommended by Carlos Morel
  
• 3.0
  Reconsidering the underestimated burden caused by neglected tropical diseases.
  Recommended by Carlos Morel